Home/Pipeline/MCED Test

MCED Test

Multi-Cancer Early Detection

Research CollaborationActive

Key Facts

Indication

Multi-Cancer Early Detection

Phase

Research Collaboration

Status

Active

Company

Mainz Biomed

About Mainz Biomed

Mainz Biomed is a commercial-stage molecular diagnostics company with a mission to transform cancer screening through convenient, at-home tests. Its core achievement is the CE-marked ColoAlert® test for colorectal cancer (CRC), which is marketed in Europe and is undergoing a pivotal FDA registration trial (ReconAAsense) in the U.S. The company's strategy is to penetrate the massive CRC screening market first, then leverage its platform for a multi-cancer early detection (MCED) pipeline, including pancreatic cancer. Recent corporate actions include a planned name change to Quantum Cyber and a $6.0 million private placement to fund operations.

View full company profile

Therapeutic Areas

Colorectal Cancer Pancreatic Cancer Multi-Cancer Early Detection

Other Multi-Cancer Early Detection Drugs

Drug	Company	Phase	Status
ALMANAC Study	Guardant Health	Research	Active
Ausel Cancer Test	Ausel Cancer Innovation	Pre-clinical	Active
GAGome for MCED	Elypta	Clinical Validation	Active
Rivela MCED Test	EXOSOMICS	Pre-clinical	Active
CancerGuard™	Exact Sciences	Pivotal Studies	Active
PATHFINDER 2	GRAIL	Interventional Study	Active
REACH/Galleri-Medicare Study	GRAIL	Prospective Cohort Study	Active
REFLECTION Study	GRAIL	Observational Study	Active
SUMMIT Study	GRAIL	Observational Cohort Study	Active
PATHFINDER Study	GRAIL	Interventional Study	Completed